APM
Avidity Partners Management Portfolio holdings
AUM
$347M
1-Year Est. Return
66.16%
This Fund
S&P 500
1 Year Est. Return
+66.16%
AUM
$439M
AUM Growth
-$59.4M
(-12%)
Holding
68
Top Buys
| 1 | +$37.3M | |
| 2 | +$17.5M | |
| 3 | +$12M | |
| 4 |
Pfizer
PFE
|
+$9.04M |
| 5 |
Kenvue
KVUE
|
+$5.41M |
Top Sells
| 1 | +$20.4M | |
| 2 | +$18.7M | |
| 3 | +$18.4M | |
| 4 |
HNGE
Hinge Health
HNGE
|
+$16.7M |
| 5 |
Boston Scientific
BSX
|
+$16.3M |
Sector Composition
| 1 | Healthcare | 99.02% |
| 2 | Consumer Staples | 0.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Doximity
DOCS
$4.75B
| – | – |
-60,000
|
|
||
52
DexCom
DXCM
$28.4B
| – | – |
-210,500
|
|
||
53
Humana
HUM
$22.5B
| – | – |
-27,600
|
|
||
54
Intuitive Surgical
ISRG
$176B
| – | – |
-27,100
|
|
||
55
Madrigal Pharmaceuticals
MDGL
$9.9B
| – | – |
-19,000
|
|
||
56
MoonLake Immunotherapeutics
MLTX
$1.25B
| – | – |
-39,000
|
|
||
57
Intellia Therapeutics
NTLA
$1.79B
| – | – |
-232,000
|
|
||
58
Organon & Co
OGN
$1.87B
| – | – |
-640,000
|
|
||
59
uniQure
QURE
$653M
| – | – |
-207,000
|
|
||
60
Ultragenyx Pharmaceutical
RARE
$2.23B
| – | – |
-154,000
|
|
||
61
Revolution Medicines
RVMD
$19.6B
| – | – |
-228,600
|
|
||
62
Reviva Pharmaceuticals
RVPH
$27.2M
| – | – |
-138,000
|
|
||
63
Soleno Therapeutics
SLNO
$2.1B
| – | – |
-32,000
|
|
||
64
Syndax Pharmaceuticals
SNDX
$1.92B
| – | – |
-150,000
|
|
||
65
Tenet Healthcare
THC
$20.4B
| – | – |
-106,000
|
|
||
|
VRNA
66
DELISTED
Verona Pharma
VRNA
| – | – |
-33,800
|
|
||
|
HNGE
67
Hinge Health
HNGE
$3.53B
| – | – |
-322,344
|
|
||
|
OMDA
68
Omada Health Inc
OMDA
$747M
| – | – |
-390,600
|
|